No More Free COVID-19 At-Home Tests, Federal Government Says
CNBC reported that the federal government is set to suspend its offer of free at-home COVID-19 tests by Friday, September 2, without congressional au
Fluidigm Reports Completed $250M Capital Infusion; To Change Name To Standard BioTools, Will Begin Trade Under Ticker ‘LAB’ As Of Apr. 6, 2022
New Trading Symbol (NASDAQ:LAB) Expected to be Effective April 6, 2022
Appoints New Management Team and Additional Board Members with Significant Experience to Reinvigorate Growth and Enhance Product Portfolio
Embarks
Fluidigm Q4 Adj. Net Loss $800K vs Loss $9.8M In Same Qtr. Last Year, Sales $38.30M Down From $44.61M YoY
Fluidigm (NASDAQ:FLDM) reported $38.30 million in sales this quarter. This is a 14.14 percent decrease over sales of $44.61 million the same period last year.
Fluidigm Files Preliminary Proxy Statement In Connection With Proposed Strategic Capital Infusion From Casdin Capital And Viking Global Investors
Fluidigm Corporation (NASDAQ:FLDM) today filed with the U.S. Securities and Exchange Commission (the “SEC”) a preliminary proxy statement for a special meeting of stockholders (the “Special
Fluidigm Granted FDA Emergency Use Authorization Approval For Advanta Dx COVID-19 EASE Assay
https://www.fda.gov/media/156093/download
52 Biggest Movers From Friday
Gainers
Knightscope, Inc. (NASDAQ: KSCP) surged 175.6% to close at $3.40 on Friday. The company, on Thursday, priced its IPO at $10 per share.
Fluidigm Announces $250M Capital Infusion From Casdin Capital And Viking Global Investors And Rebranding To Standard BioTools Inc.
Mission to Reinvigorate Growth through Optimization of Mass Cytometry and Microfluidics Platforms and Portfolio Expansion via Strategic Acquisitions
Dr. Michael Egholm, Former CTO of Danaher Life Sciences, to
Fluidigm Shares Gain As Preliminary Q4, FY21 Sales Exceed Expectations
Fluidigm Corp (NASDAQ: FLDM)
Stocks That Hit 52-Week Lows On Friday
Before 10 am on Friday, 110 companies set new 52-week lows.